Literature DB >> 1747138

Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis.

J P Brodeur1, S Ruddy, L B Schwartz, G Moxley.   

Abstract

To determine whether complement turnover in synovial fluids of patients with rheumatoid arthritis (RA) reflects activation by the classical or alternative pathway, we used novel immunoassays to measure products of complement activation (the membrane attack complex SC5b-9 and the cleavage fragments Bb and C4d). Mean synovial fluid levels of SC5b-9 were more than 8 times higher in RA than in crystal-induced arthritis (gout and pseudogout) and over 16 times higher than in degenerative joint disease (DJD). Similarly, Bb levels were more than 3 times higher in RA synovial fluids than in crystal-induced arthritis and over 7 times higher than in DJD. Levels of C4d did not differ among the groups. SC5b-9 levels correlated with synovial fluid C3 anaphylatoxin (C3a), Bb, and C4d levels (r = 0.81, 0.62, and 0.51, respectively). In patients with RA, synovial fluid SC5b-9 levels correlated with C3a and Bb (r = 0.6 and 0.56, respectively) but not with C4d. Therefore, novel assays for complement activation indicate that both classical and alternative pathways are involved in complement turnover and that the alternative pathway contributes more to complement activation in RA than in DJD or crystal-induced arthritis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1747138     DOI: 10.1002/art.1780341209

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  35 in total

Review 1.  Complement in the immunopathogenesis of rheumatic disease.

Authors:  Gunnar Sturfelt; Lennart Truedsson
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

2.  Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA).

Authors:  M A Friese; J Hellwage; T S Jokiranta; S Meri; H J Müller-Quernheim; H H Peter; H Eibel; P F Zipfel
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59.

Authors:  M Mizuno; K Nishikawa; B P Morgan; S Matsuo
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

4.  C4d deposits mark sites of meniscal tissue disintegration.

Authors:  Anja Dankof; Veit Krenn
Journal:  Virchows Arch       Date:  2006-05-04       Impact factor: 4.064

5.  Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane.

Authors:  Y T Konttinen; A Ceponis; S Meri; A Vuorikoski; P Kortekangas; T Sorsa; A Sukura; S Santavirta
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

Review 6.  How novel structures inform understanding of complement function.

Authors:  Elena Goicoechea de Jorge; Hugo Yebenes; Marina Serna; Agustín Tortajada; Oscar Llorca; Santiago Rodríguez de Córdoba
Journal:  Semin Immunopathol       Date:  2017-08-14       Impact factor: 9.623

7.  Apolipoprotein E Triggers Complement Activation in Joint Synovial Fluid of Rheumatoid Arthritis Patients by Binding C1q.

Authors:  Leonie M Vogt; Ewa Kwasniewicz; Simone Talens; Carsten Scavenius; Ewa Bielecka; Kristina N Ekdahl; Jan J Enghild; Matthias Mörgelin; Tore Saxne; Jan Potempa; Anna M Blom
Journal:  J Immunol       Date:  2020-04-06       Impact factor: 5.422

8.  Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.

Authors:  C L Harris; A S Williams; S M Linton; B P Morgan
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

9.  Release of endogenous anti-inflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis.

Authors:  M A Friese; T Manuelian; S Junnikkala; J Hellwage; S Meri; H H Peter; D L Gordon; H Eibel; P F Zipfel
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

Review 10.  Novel mechanisms of action of the biologicals in rheumatic diseases.

Authors:  Cecilia Beatrice Chighizola; Ennio Giulio Favalli; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.